---
schema_version: "secwatch.filing_event.v1"
accession: "0001625101-22-000065"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:03:51.817659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports Q3 net loss $18M, tightens focus on cardiac ablation, secures $65M loan from chairman

## Summary
- Q3 GAAP net loss $18.0M vs $14.3M in prior year; no revenue recorded.
- Strategic pivot to cardiac cellular ablation for atrial fibrillation; dermatology business inventory reserve of $7.2M.
- Entered $65M term loan at 5% interest, due March 2024, from Executive Chairman Robert Duggan.
- Appointed Kevin Danahy as CEO, Darrin Uecker as CTO, and Robert Duggan as Executive Chairman.
- Anticipates quarterly cash burn ~$8M from Q1 2023; cash $69.2M at Sep 30 vs $28.6M at Dec 31, 2021.

## SEC filing metadata
- accession: 0001625101-22-000065
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/0001625101-22-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/plse-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625101-22-000065
- JSON: https://secwatch.observer/filing/0001625101-22-000065.json
- Plain text: https://secwatch.observer/filing/0001625101-22-000065.txt

## Key facts
- Earnings Releases
  PULSE BIOSCIENCES, INC. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Pulse Biosciences, Inc. announced its financial results for the fiscal quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/0001625101-22-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.